Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Clopidogrel

Cattaneo M (2004) Aspirin and clopidogrel efficacy, safety, and the issue of drag resistance. Arterioscler Thromb Vase Biol 24 1980-1987... [Pg.171]

C7H5CIO 89-98-5) see Amlodipine Clobenzorex Clopidogrel hydrogensulfate Cloxacillin 4-chlorobenzaldehyde... [Pg.2323]

CNNa 143-33-9) see Alclofenac Alpidem Amphetaminil Atorvastatin calcium Azatadine Calcium pantothenate Carnitine Clopidogrel hydrogensulfate Clortermine Dexrazoxane Diclofenac Diloxanide Edetic acid Epinastine hydrochloride Ethosuximide Ethotoin Fenoprofen Ibuprofen Irbesartan Ketoprofen Lonazolac Mephenytoin Mepindolol Montelukast sodium Nabilone Oxymetazoline Paramethadione Pentorex Saquinavir Suprofen Thiamphenicol Tolmetin Trimazosin Zolpidem sodium cyanoborohydride... [Pg.2441]

CjHyNS 30433-91-1) see Clopidogrel hydrogensulfate 2-[2-(2-thienyl)ethyl]benzoic acid (C 3H,202S 1622-54-4) see Pizotifen 2-thienylglyoxalic acid... [Pg.2446]

C4H4S 110-02-1). see Clopidogrel hydrogensulfate Oxitefonium bromide Penthienate methobromide Suprofen 2-Thiophenecarboxylic acid Tiaprofenic acid Ticlopidine Tiemonium iodide Tienilic acid... [Pg.2446]

Shi D, Yang J, Yang D, LeCluyse EL, Black C, You L, Akhlaghi F, Yan B (2006) Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel. J Pharmacol Exp Ther 319 1477-1484... [Pg.152]

PROFESS is an ongoing large randomized trial examining combination ER-DP plus aspirin therapy compared with clopidogrel (each group also with or without telmisartan, an angiotensin receptor antagonist) for the secondary prevention of early and late recurrent stroke, and other vascular events. [Pg.148]

Clopidogrel also inhibits the P2Yj2 ADP receptor following hepatic activation in... [Pg.148]

Clopidogrel s antiplatelet effect is maximal after 3-5 days of therapy. [Pg.148]

The CAPRIE trial found that compared to aspirin (325 mg daily), clopidogrel (75 mg daily) was associated with RRR of 8.7% p = 0.043) for the composite endpoint of ischemic stroke, Ml, or vascular death among 19,185 subjects with stroke, MI, or peripheral arterial disease, but no significant reduction in the composite endpoint in the subgroup with stroke (RRR 7.3%, p = 0.26). No comparison of clopidogrel with aspirin in the acute stroke period was performed. Furthermore, stroke as an endoint was not significantly reduced in the stroke patients entered in this trial (RRR 8.0%, p = NS). [Pg.149]

Subgroup analyses of the MATCH data suggested a 12% risk reduction in recurrent vascular events at 18 months in patients with large vessel disease who were given combination aspirin and clopidogrel compared with clopidogrel alone. [Pg.152]

Savi P, Pereillo JM, Uzabiaga ME, Combalbert J, Picard C, Maffrand JP, Pascal M, Herbert JM. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000 84 891-896. [Pg.159]

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996 348(9038) 1329-1339. [Pg.159]

Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, Leys D, Matias-Guiu J, Rupprecht HJ MATCH investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischemic stroke or transient ischemic attack in high-risk patients (MATCH) randomised, double-blind, placebo-controlled trial. Lancet 2004 364(9431) 331-337. [Pg.159]

Markus HS, Droste DW, Kaps M, Larrue V, Lees KR, Siebler M, Ringelstein EB. Dual antiplatelet therapy with clopidogrel and aspirin in s3miptomatic carotid stenosis evaluated using doppler embolic signal detection the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial. Circulation 2005 lll(17) 2233-2240. [Pg.212]

The industrial production of CLOPIDOGREL (PLAVIX ) is an interesting example which demonstrates the synthetic potential of non-racemic cyanohydrins (Scheme 5). ... [Pg.146]

In the first step, (R)-2-chlorobenzaldehyde cyanohydrin is prepared by the almond meal-catalyzed addition of HCN to 2-chlorobenzaldehyde. The cyanohydrin is then transformed into the corresponding 2-hydroxy ester by Pinner reaction. Subsequently, the hydroxy group is activated by sulfonylafion and reacted with tetrahydrothieno[3.2-c]pyridine to give, under complete inversion of configuration, the (5 ) — a-amino acid derivative CLOPIDOGREL. ... [Pg.146]

Scheme 5 Stereoselective synthesis of Clopidogrel (Plavix ) starting from... Scheme 5 Stereoselective synthesis of Clopidogrel (Plavix ) starting from...
See other pages where Clopidogrel is mentioned: [Pg.228]    [Pg.23]    [Pg.168]    [Pg.170]    [Pg.917]    [Pg.1053]    [Pg.1198]    [Pg.526]    [Pg.526]    [Pg.527]    [Pg.527]    [Pg.2299]    [Pg.2301]    [Pg.2334]    [Pg.2334]    [Pg.2334]    [Pg.2334]    [Pg.2335]    [Pg.2380]    [Pg.2396]    [Pg.2404]    [Pg.2411]    [Pg.2413]    [Pg.2445]    [Pg.2446]    [Pg.2446]    [Pg.2446]    [Pg.149]    [Pg.151]    [Pg.159]    [Pg.207]    [Pg.23]    [Pg.24]   
See also in sourсe #XX -- [ Pg.43 , Pg.59 , Pg.291 ]

See also in sourсe #XX -- [ Pg.45 , Pg.67 ]

See also in sourсe #XX -- [ Pg.150 ]

See also in sourсe #XX -- [ Pg.116 ]

See also in sourсe #XX -- [ Pg.203 , Pg.367 , Pg.587 , Pg.685 ]

See also in sourсe #XX -- [ Pg.584 ]

See also in sourсe #XX -- [ Pg.183 ]

See also in sourсe #XX -- [ Pg.2 , Pg.3 , Pg.4 , Pg.5 , Pg.6 , Pg.7 , Pg.8 , Pg.9 ]

See also in sourсe #XX -- [ Pg.273 ]

See also in sourсe #XX -- [ Pg.116 ]

See also in sourсe #XX -- [ Pg.350 , Pg.354 ]

See also in sourсe #XX -- [ Pg.14 ]

See also in sourсe #XX -- [ Pg.209 , Pg.210 ]

See also in sourсe #XX -- [ Pg.161 ]

See also in sourсe #XX -- [ Pg.59 , Pg.60 , Pg.144 , Pg.145 , Pg.146 , Pg.147 , Pg.148 , Pg.517 ]

See also in sourсe #XX -- [ Pg.16 , Pg.128 , Pg.130 , Pg.131 , Pg.132 , Pg.133 , Pg.134 ]

See also in sourсe #XX -- [ Pg.448 ]

See also in sourсe #XX -- [ Pg.453 ]

See also in sourсe #XX -- [ Pg.348 ]

See also in sourсe #XX -- [ Pg.89 ]

See also in sourсe #XX -- [ Pg.154 ]

See also in sourсe #XX -- [ Pg.2 , Pg.3 , Pg.4 , Pg.5 , Pg.6 , Pg.7 , Pg.8 , Pg.9 ]

See also in sourсe #XX -- [ Pg.257 , Pg.285 , Pg.287 ]

See also in sourсe #XX -- [ Pg.124 , Pg.140 ]

See also in sourсe #XX -- [ Pg.263 ]

See also in sourсe #XX -- [ Pg.486 , Pg.583 ]

See also in sourсe #XX -- [ Pg.32 , Pg.167 ]

See also in sourсe #XX -- [ Pg.3 , Pg.3 , Pg.3 , Pg.29 , Pg.285 , Pg.320 ]

See also in sourсe #XX -- [ Pg.587 ]

See also in sourсe #XX -- [ Pg.564 ]

See also in sourсe #XX -- [ Pg.100 , Pg.736 ]

See also in sourсe #XX -- [ Pg.24 ]

See also in sourсe #XX -- [ Pg.645 , Pg.655 ]

See also in sourсe #XX -- [ Pg.73 ]

See also in sourсe #XX -- [ Pg.7 , Pg.9 ]

See also in sourсe #XX -- [ Pg.166 , Pg.234 , Pg.691 ]

See also in sourсe #XX -- [ Pg.148 ]

See also in sourсe #XX -- [ Pg.253 , Pg.621 ]

See also in sourсe #XX -- [ Pg.275 ]

See also in sourсe #XX -- [ Pg.308 , Pg.310 ]

See also in sourсe #XX -- [ Pg.116 ]

See also in sourсe #XX -- [ Pg.260 , Pg.267 , Pg.837 , Pg.838 , Pg.838 ]

See also in sourсe #XX -- [ Pg.164 , Pg.165 ]

See also in sourсe #XX -- [ Pg.100 , Pg.736 ]

See also in sourсe #XX -- [ Pg.11 , Pg.125 , Pg.187 ]

See also in sourсe #XX -- [ Pg.47 ]

See also in sourсe #XX -- [ Pg.234 ]

See also in sourсe #XX -- [ Pg.212 , Pg.213 , Pg.571 , Pg.580 , Pg.670 ]

See also in sourсe #XX -- [ Pg.138 ]

See also in sourсe #XX -- [ Pg.818 ]

See also in sourсe #XX -- [ Pg.193 , Pg.237 ]

See also in sourсe #XX -- [ Pg.175 , Pg.912 ]

See also in sourсe #XX -- [ Pg.147 ]

See also in sourсe #XX -- [ Pg.45 ]

See also in sourсe #XX -- [ Pg.47 ]

See also in sourсe #XX -- [ Pg.1122 ]

See also in sourсe #XX -- [ Pg.85 ]

See also in sourсe #XX -- [ Pg.393 , Pg.394 , Pg.396 ]



SEARCH



2-oxo-clopidogrel

Acute coronary syndromes clopidogrel

Antiplatelet agents clopidogrel

Antiplatelet drugs clopidogrel

Atorvastatin Clopidogrel

Beta blockers Clopidogrel

Bleeding clopidogrel

Bupropion Clopidogrel

Cilostazol Clopidogrel

Clinical trials clopidogrel

Clopidogrel (Plavix

Clopidogrel (Plavix) Enzymatic Preparation of 2-Chloromandelic Acid Esters

Clopidogrel Acetylsalicylic acid

Clopidogrel Aspirin

Clopidogrel Calcium-channel blockers

Clopidogrel Coumarins

Clopidogrel Digoxin

Clopidogrel Eptifibatide

Clopidogrel Foods

Clopidogrel Heparin

Clopidogrel NSAIDs)

Clopidogrel Rosuvastatin

Clopidogrel Simvastatin

Clopidogrel Statins

Clopidogrel Vasodilators

Clopidogrel Warfarin

Clopidogrel adverse effects

Clopidogrel and metoprolol

Clopidogrel and proton pump inhibitors

Clopidogrel as adjunctive reperfusion

Clopidogrel bisulfate

Clopidogrel bisulfate (Plavix

Clopidogrel clinical relevance

Clopidogrel clinical studies

Clopidogrel contraindications

Clopidogrel coronary stenting

Clopidogrel cytochrome

Clopidogrel derivatives

Clopidogrel dosage

Clopidogrel dosing

Clopidogrel drug interactions

Clopidogrel heart failure

Clopidogrel implantation

Clopidogrel in acute coronary syndromes

Clopidogrel indications

Clopidogrel interactions

Clopidogrel liver

Clopidogrel medicines)

Clopidogrel metabolism

Clopidogrel neurology

Clopidogrel nonresponsiveness

Clopidogrel pharmacology

Clopidogrel platelet response

Clopidogrel resistance

Clopidogrel response variability

Clopidogrel side effects

Clopidogrel structure

Clopidogrel studies

Clopidogrel synthesis

Clopidogrel thienopyridines

Clopidogrel thrombocytopenia with

Clopidogrel with warfarin

Clopidogrel, safety

Coronary artery disease clopidogrel

Coronary stents clopidogrel

Gastrointestinal bleeding clopidogrel

Ischemic stroke clopidogrel

Myocardial infarction clopidogrel

Peripheral arterial disease clopidogrel

Platelet inhibition clopidogrel

Plavix - Clopidogrel sulfate

Sanofi-Synthelabo v. Apotex, Inc. (clopidogrel bisulfate)

Stents clopidogrel

Stroke clopidogrel

Syntheses of clopidogrel

Transient ischemic attack clopidogrel

© 2024 chempedia.info